| Title: |
Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial. |
| Authors: |
Javier Basterra-Gortari, F.1,2, Ruiz-Canela, Miguel1,3, Martínez-González, Miguel A.1,3,4, Babio, Nancy3,5, Sorlí, José V.3,6, Fito, Montserrat3,7, Ros, Emilio3,8, Gómez-Gracia, Enrique3,9, Fiol, Miquel3,10, Lapetra, José3,11, Estruch, Ramón3,12, Serra-Majem, Luis3,13,14, Pinto, Xavier3,15, González, José I.3,6, Bulló, Mónica3,5, Castañer, Olga3,7, Alonso-Gómez, Ángel3,16, Forga, Luis17, Arós, Fernando3,16,18 lfaborau@gmail.com, Basterra-Gortari, F Javier19,20 (AUTHOR) |
| Source: |
Diabetes Care. Aug2019, Vol. 42 Issue 8, p1390-1397. 8p. 1 Diagram, 1 Chart, 2 Graphs. |
| Subject Terms: |
*TYPE 2 diabetes, *SUBGROUP analysis (Experimental design), *OLIVE oil, *DRUGS |
| Abstract: |
Objective: To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications.Research Design and Methods: From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical analysis. In multivariable time-to-event survival models, we assessed two outcomes: 1) introduction of the first glucose-lowering medication (oral or injectable) among participants on lifestyle management at enrollment and 2) insulin initiation.Results: After a median follow-up of 3.2 years, in multivariable analyses adjusting for baseline characteristics and propensity scores, the hazard ratios (HRs) of starting a first glucose-lowering medication were 0.78 (95% CI 0.62-0.98) for Med-EatPlan + EVOO and 0.89 (0.71-1.12) for Med-EatPlan + nuts, compared with the control eating plan. After a median follow-up of 5.1 years, the adjusted HRs of starting insulin treatment were 0.87 (0.68-1.11) for Med-EatPlan + EVOO and 0.89 (0.69-1.14) for Med-EatPlan + nuts compared with the control eating plan.Conclusions: Among participants with type 2 diabetes, a Med-EatPlan + EVOO may delay the introduction of new-onset glucose-lowering medications. The Med-EatPlan did not result in a significantly lower need for insulin. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes Care is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
